Literature DB >> 17082927

[Pharmacotherapy for schizophrenia].

W W Fleischhacker1, W Hummer.   

Abstract

The management of schizophrenia patients remains one of the great challenges in psychiatry. Despite the undisputed effectiveness of antipsychotic drugs, patients and their physicians still face considerable difficulties mainly related to incomplete or lacking treatment response and the inability to predict the individual efficacy and tolerability. In this manuscript we review the key elements of pharmacological treatment of this disorder, encompassing acute and long-term management as well as specific management problems ranging from acutely violent patients to treatment-resistant subjects. Along with general treatment principles, the document provides specific information regarding efficacy and safety features of antipsychotics. Many of the currently available treatment recommendations/guidelines are based on the evidence reviewed here. This review is meant to serve as a guide for clinicians involved in managing schizophrenia, whether in a psychiatric hospital setting or as family physicians in private practice.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17082927     DOI: 10.1007/s00115-006-2194-8

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  115 in total

1.  High-dose treatment with haloperidol: the effect of dose reduction.

Authors:  J Volavka; T B Cooper; P Czobor; J P Lindenmayer; L L Citrome; P Mohr; N Bark
Journal:  J Clin Psychopharmacol       Date:  2000-04       Impact factor: 3.153

Review 2.  Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses.

Authors:  R J Baldessarini; B M Cohen; M H Teicher
Journal:  Arch Gen Psychiatry       Date:  1988-01

3.  Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol.

Authors:  C M Beasley; M A Dellva; R N Tamura; H Morgenstern; W M Glazer; K Ferguson; G D Tollefson
Journal:  Br J Psychiatry       Date:  1999-01       Impact factor: 9.319

4.  Clinical use of high-dose neuroleptics.

Authors:  S R Hirsch; T R Barnes
Journal:  Br J Psychiatry       Date:  1994-01       Impact factor: 9.319

5.  Neuroleptic withdrawal in schizophrenic patients. A review of the literature.

Authors:  P L Gilbert; M J Harris; L A McAdams; D V Jeste
Journal:  Arch Gen Psychiatry       Date:  1995-03

6.  Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group.

Authors:  D L Zimbroff; J M Kane; C A Tamminga; D G Daniel; R J Mack; P J Wozniak; T B Sebree; B A Wallin; K B Kashkin
Journal:  Am J Psychiatry       Date:  1997-06       Impact factor: 18.112

7.  Clozapine and risperidone: combination/augmentation treatment of refractory schizophrenia: a preliminary observation.

Authors:  S Raskin; G Katz; Z Zislin; H Y Knobler; R Durst
Journal:  Acta Psychiatr Scand       Date:  2000-04       Impact factor: 6.392

Review 8.  Clozapine: a comparison with other novel antipsychotics.

Authors:  W W Fleischhacker
Journal:  J Clin Psychiatry       Date:  1999       Impact factor: 4.384

Review 9.  The promise of atypical antipsychotics: fewer side effects mean enhanced compliance and improved functioning.

Authors:  Leslie Citrome; Jan Volavka
Journal:  Postgrad Med       Date:  2004-10       Impact factor: 3.840

Review 10.  Depot antipsychotic drugs. Place in therapy.

Authors:  J M Davis; L Matalon; M D Watanabe; L Blake; L ] Metalon L [corrected to Matalon
Journal:  Drugs       Date:  1994-05       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.